CJC-1295 + Ipamorelin

Description

CJC-1295 + Ipamorelin Reference Blend | Dual Somatotroph Receptor Ligands

The CJC-1295 + Ipamorelin combination pairs a long-acting GHRH receptor agonist (CJC-1295, DAC-modified) with a selective GHSR-1a agonist (Ipamorelin) in a single pre-formulated reference blend. Both receptors are co-expressed on anterior pituitary somatotrophs and signal through distinct intracellular pathways — GHRH via cAMP/adenylyl cyclase and GHSR-1a via phospholipase C/calcium — making this combination a tool for dual-pathway somatotroph signaling studies.

Research Rationale

Published preclinical data consistently demonstrate additive to synergistic GH secretion when GHRH receptors and GHSR-1a are co-activated — a receptor-level interaction of mechanistic interest in somatotroph pharmacology. The combination allows researchers to probe this synergy with well-characterized individual ligand pharmacokinetics.

Specifications

• Form: Lyophilized blend
• Purity: ≥98% each component (HPLC verified)
• Storage: 2–8°C refrigerated

For laboratory research use only. Not for human or veterinary use.